Overview

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers"). 60% of participants will receive Niagen and 40% will receive PBO. Outcomes will consist of standardized cognitive, neuropsychiatric, physical, functional and biomarker assessments.

Phase:

Phase 4

Details

Lead Sponsor:

Massachusetts General Hospital

Treatments:

Niacinamide